Can-Fite BioPharma adjourns 2026 shareholder meeting

Can-Fite BioPharma Ltd. held its 2026 Annual General Meeting of Shareholders on May 28, 2026, but the meeting was adjourned because there were not enough shareholders present to meet the required quorum.

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. held its 2026 Annual General Meeting of Shareholders on May 28, 2026, but the meeting was adjourned because there were not enough shareholders present to meet the required quorum. The meeting is scheduled to reconvene on June 4, 2026 at 3:00 p.m. Israel time at the company’s offices in Ramat Gan, Israel.

Key Terms

foreign private issuer, Annual General Meeting of Shareholders, quorum, Form 20-F

4 terms

foreign private issuer regulatory

"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Annual General Meeting of Shareholders financial

"convened the 2026 Annual General Meeting of Shareholders (the “Meeting”)."

quorum regulatory

"the Meeting was adjourned for one week ... due to lack of quorum."

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

Form 20-F regulatory

"whether the registrant files or will file annual reports under cover Form 20-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Can-Fite BioPharma Ltd. (CANF) report in this Form 6-K?

Can-Fite BioPharma reported that its 2026 Annual General Meeting of Shareholders convened on May 28, 2026 but was adjourned due to lack of quorum, and will reconvene on June 4, 2026.

Why was Can-Fite BioPharma’s 2026 Annual General Meeting adjourned?

The 2026 Annual General Meeting of Shareholders was adjourned because a quorum was not present. Without sufficient shareholder participation to meet quorum requirements, the company could not conduct formal business at the meeting.

When will Can-Fite BioPharma (CANF) reconvene its 2026 shareholder meeting?

The company plans to reconvene the 2026 Annual General Meeting of Shareholders on June 4, 2026 at 3:00 p.m. Israel time, at its offices at 26 Ben Gurion Street, Ramat Gan, Israel.

Where is Can-Fite BioPharma’s reconvened 2026 Annual General Meeting being held?

The reconvened 2026 Annual General Meeting will be held at Can-Fite BioPharma’s offices at 26 Ben Gurion Street, Ramat Gan, Israel, on June 4, 2026 at 3:00 p.m. Israel time.

What type of SEC filer is Can-Fite BioPharma Ltd.?

Can-Fite BioPharma Ltd. is a foreign private issuer that files its annual reports with the SEC on Form 20-F, as indicated in the Form 6-K cover information.

Who signed the May 2026 Form 6-K for Can-Fite BioPharma (CANF)?

The Form 6-K dated May 28, 2026 was signed on behalf of Can-Fite BioPharma Ltd. by Motti Farbstein, who serves as Chief Executive Officer and Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of May 2026

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On May 28, 2026, Can-Fite BioPharma Ltd. (the “Company”) convened the 2026 Annual General Meeting of Shareholders (the “Meeting”). However, the Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Meeting will be reconvened on Thursday, June 4, 2026 at 3:00 p.m., Israel time at the Company’s offices located at 26 Ben Gurion Street, Ramat Gan, Israel.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 28, 2026	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

2